Pfizer (NYSE:PFE) Rating Reiterated by Cantor Fitzgerald

Pfizer (NYSE:PFE)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They currently have a $75.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 151.26% from the company’s current price.

Several other analysts have also commented on the stock. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday, October 16th. Barclays reduced their price objective on Pfizer from $35.00 to $34.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 1st. Morgan Stanley cut their target price on Pfizer from $39.00 to $37.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 1st. StockNews.com began coverage on Pfizer in a research report on Thursday, October 5th. They issued a “hold” rating for the company. Finally, Wells Fargo & Company cut their price objective on Pfizer from $39.00 to $35.00 and set an “equal weight” rating on the stock in a report on Monday, October 16th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $42.50.

Pfizer Price Performance

PFE traded down $0.07 during trading on Monday, reaching $29.85. The stock had a trading volume of 11,720,131 shares, compared to its average volume of 25,485,195. The stock has a 50 day moving average of $31.97 and a two-hundred day moving average of $35.23. The company has a quick ratio of 2.05, a current ratio of 2.38 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $168.55 billion, a price-to-earnings ratio of 16.30, a price-to-earnings-growth ratio of 1.91 and a beta of 0.63. Pfizer has a 1-year low of $28.93 and a 1-year high of $54.93.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.15. Pfizer had a return on equity of 16.72% and a net margin of 15.30%. The business had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $13.77 billion. As a group, equities analysts anticipate that Pfizer will post 1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Several large investors have recently made changes to their positions in PFE. Front Street Capital Management Inc. raised its holdings in Pfizer by 4.3% during the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares in the last quarter. Madison Wealth Management lifted its holdings in Pfizer by 0.6% in the 1st quarter. Madison Wealth Management now owns 42,810 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 262 shares during the last quarter. Capital Planning Advisors LLC boosted its position in Pfizer by 1.8% during the second quarter. Capital Planning Advisors LLC now owns 16,091 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 281 shares during the period. Graves Light Lenhart Wealth Inc. grew its holdings in Pfizer by 1.4% during the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 281 shares during the last quarter. Finally, V Wealth Advisors LLC raised its position in shares of Pfizer by 0.9% in the second quarter. V Wealth Advisors LLC now owns 31,001 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 282 shares during the period. Institutional investors own 68.05% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.